ea0011p183 | Clinical practise and governance | ECE2006
Jaobeit JW
, Epe M
, Hugo U
, Ludwig M
, Schulte HM
Introduction: Intramuscular Testosterone Undecanoate (TU, Nebido®) has become available in November 2004 in Europe for the treatment of male hypogonadism. Continuous physiological hormone replacement is necessary for transgender patients, both prior to the gender adjustment operation and for the remainder of the individuals lifetime. The administration of long-acting TU therefore stood to reason as part of cross-gender testosterone therapy for female-to-m...